Ozempic

Caloric Restriction, at least one weight-related comorbid condition, Obesity + 6 more
Treatment
6 FDA approvals
20 Active Studies for Ozempic

What is Ozempic

SemaglutideThe Generic name of this drug
Treatment SummarySemaglutide is a medication used to treat type 2 diabetes. It works by stimulating insulin production and reducing blood sugar levels. It is available in two forms: injections that are given once a week and tablets that are taken once a day. Clinical trials have shown that semaglutide can lower the levels of glycosylated hemoglobin (HbA1c) and reduce body weight. In 2021, semaglutide was approved by the FDA and Health Canada for use in adults with general obesity or overweight who have at least one weight-related condition. This makes semaglutide the first drug
Ozempicis the brand name
image of different drug pills on a surface
Ozempic Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Ozempic
Semaglutide
2017
19

Approved as Treatment by the FDA

Semaglutide, commonly known as Ozempic, is approved by the FDA for 6 uses including Type 2 Diabetes Mellitus and Cardiovascular Events .
Type 2 Diabetes Mellitus
Cardiovascular Events
Type 2 Diabetes
Cardiovascular Diseases
Physical Activity
Used in combination with other therapies
Diet
Used in combination with other therapies

Effectiveness

How Ozempic Affects PatientsSemaglutide helps to reduce levels of HbA1c, blood pressure, and body weight. It does this by increasing insulin production and decreasing the amount of glucagon in the body. It also lowers triglycerides and VLDL cholesterol, which can help improve cardiovascular health. There is a risk of developing medullary thyroid cell cancer, pancreatitis, and dehydration while taking semaglutide. It is important to stay hydrated and seek medical attention right away if experiencing abdominal pain. Additionally, this drug may affect how other drugs taken orally are absorbed, so it's important to monitor for both positive and negative
How Ozempic works in the bodySemaglutide helps to keep blood sugar levels in check by stimulating the pancreas to produce insulin. It also slows down the digestion of food and reduces the amount of glucagon released after meals. Semaglutide binds to the GLP-1 receptor in the body, activating several processes that lower blood sugar. Additionally, semaglutide may reduce the progression of atherosclerosis, a type of heart disease, by decreasing inflammation and gut permeability. Finally, semaglutide can also lead to weight loss through its effects on appetite and food cravings.

When to interrupt dosage

The dosage of Ozempic is contingent upon the diagnosed issue, such as Type 2 Diabetes, at least one weight-related comorbid condition and reduced-calorie diet. The sum of medication also fluctuates in accordance with the technique of delivery (e.g. Solution - Subcutaneous or Subcutaneous) specified in the table beneath.
Condition
Dosage
Administration
Obesity
, 1.34 mg/mL, 1.0 mg, 3.0 mg, 7.0 mg, 14.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/pump actuation, 5.0 mg/mL, 2.5 mg/mL, 24.0 mg/mL, 10.0 mg/mL, 17.0 mg/mL, 2.68 mg/mL, 2.4 mg, 1.7 mg, 20.0 mg/mL
Solution, Solution - Subcutaneous, , Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Tablet - Oral, Tablet, Oral, Injection, powder, lyophilized, for suspension - Oral, Injection, powder, lyophilized, for suspension
Physical Activity
, 1.34 mg/mL, 1.0 mg, 3.0 mg, 7.0 mg, 14.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/pump actuation, 5.0 mg/mL, 2.5 mg/mL, 24.0 mg/mL, 10.0 mg/mL, 17.0 mg/mL, 2.68 mg/mL, 2.4 mg, 1.7 mg, 20.0 mg/mL
Solution, Solution - Subcutaneous, , Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Tablet - Oral, Tablet, Oral, Injection, powder, lyophilized, for suspension - Oral, Injection, powder, lyophilized, for suspension
Type 2 Diabetes
, 1.34 mg/mL, 1.0 mg, 3.0 mg, 7.0 mg, 14.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/pump actuation, 5.0 mg/mL, 2.5 mg/mL, 24.0 mg/mL, 10.0 mg/mL, 17.0 mg/mL, 2.68 mg/mL, 2.4 mg, 1.7 mg, 20.0 mg/mL
Solution, Solution - Subcutaneous, , Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Tablet - Oral, Tablet, Oral, Injection, powder, lyophilized, for suspension - Oral, Injection, powder, lyophilized, for suspension
Diet
, 1.34 mg/mL, 1.0 mg, 3.0 mg, 7.0 mg, 14.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/pump actuation, 5.0 mg/mL, 2.5 mg/mL, 24.0 mg/mL, 10.0 mg/mL, 17.0 mg/mL, 2.68 mg/mL, 2.4 mg, 1.7 mg, 20.0 mg/mL
Solution, Solution - Subcutaneous, , Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Tablet - Oral, Tablet, Oral, Injection, powder, lyophilized, for suspension - Oral, Injection, powder, lyophilized, for suspension
Chronic Weight Management therapy
, 1.34 mg/mL, 1.0 mg, 3.0 mg, 7.0 mg, 14.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/pump actuation, 5.0 mg/mL, 2.5 mg/mL, 24.0 mg/mL, 10.0 mg/mL, 17.0 mg/mL, 2.68 mg/mL, 2.4 mg, 1.7 mg, 20.0 mg/mL
Solution, Solution - Subcutaneous, , Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Tablet - Oral, Tablet, Oral, Injection, powder, lyophilized, for suspension - Oral, Injection, powder, lyophilized, for suspension
Cardiovascular Diseases
, 1.34 mg/mL, 1.0 mg, 3.0 mg, 7.0 mg, 14.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/pump actuation, 5.0 mg/mL, 2.5 mg/mL, 24.0 mg/mL, 10.0 mg/mL, 17.0 mg/mL, 2.68 mg/mL, 2.4 mg, 1.7 mg, 20.0 mg/mL
Solution, Solution - Subcutaneous, , Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Tablet - Oral, Tablet, Oral, Injection, powder, lyophilized, for suspension - Oral, Injection, powder, lyophilized, for suspension
Caloric Restriction
, 1.34 mg/mL, 1.0 mg, 3.0 mg, 7.0 mg, 14.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/pump actuation, 5.0 mg/mL, 2.5 mg/mL, 24.0 mg/mL, 10.0 mg/mL, 17.0 mg/mL, 2.68 mg/mL, 2.4 mg, 1.7 mg, 20.0 mg/mL
Solution, Solution - Subcutaneous, , Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Tablet - Oral, Tablet, Oral, Injection, powder, lyophilized, for suspension - Oral, Injection, powder, lyophilized, for suspension
at least one weight-related comorbid condition
, 1.34 mg/mL, 1.0 mg, 3.0 mg, 7.0 mg, 14.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/pump actuation, 5.0 mg/mL, 2.5 mg/mL, 24.0 mg/mL, 10.0 mg/mL, 17.0 mg/mL, 2.68 mg/mL, 2.4 mg, 1.7 mg, 20.0 mg/mL
Solution, Solution - Subcutaneous, , Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Tablet - Oral, Tablet, Oral, Injection, powder, lyophilized, for suspension - Oral, Injection, powder, lyophilized, for suspension
Cardiovascular Events
, 1.34 mg/mL, 1.0 mg, 3.0 mg, 7.0 mg, 14.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/pump actuation, 5.0 mg/mL, 2.5 mg/mL, 24.0 mg/mL, 10.0 mg/mL, 17.0 mg/mL, 2.68 mg/mL, 2.4 mg, 1.7 mg, 20.0 mg/mL
Solution, Solution - Subcutaneous, , Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Tablet - Oral, Tablet, Oral, Injection, powder, lyophilized, for suspension - Oral, Injection, powder, lyophilized, for suspension

Warnings

Ozempic Contraindications
Condition
Risk Level
Notes
Multiple Endocrine Neoplasia
Do Not Combine
Thyroid Neoplasms
Do Not Combine
Medullary carcinoma of thyroid
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Semaglutide may interact with Pulse Frequency
There are 20 known major drug interactions with Ozempic.
Common Ozempic Drug Interactions
Drug Name
Risk Level
Description
Acetohexamide
Moderate
Semaglutide may increase the hypoglycemic activities of Acetohexamide.
Carbutamide
Moderate
Semaglutide may increase the hypoglycemic activities of Carbutamide.
Chlorpropamide
Moderate
Semaglutide may increase the hypoglycemic activities of Chlorpropamide.
Englitazone
Moderate
The risk or severity of hypoglycemia can be increased when Semaglutide is combined with Englitazone.
Fluconazole
Moderate
The risk or severity of hypoglycemia can be increased when Semaglutide is combined with Fluconazole.
Ozempic Toxicity & Overdose RiskSome people have overdosed on Semaglutide and experienced nausea as the primary symptom. All those who have overdosed have recovered fully with the help of medical care. It can take up to one week for Semaglutide to leave the body, so observation and treatment may be necessary for a while. There is no specific antidote for an overdose on this drug.
image of a doctor in a lab doing drug, clinical research

Ozempic Novel Uses: Which Conditions Have a Clinical Trial Featuring Ozempic?

196 active studies are currently underway to assess the effectiveness of Ozempic in treating Disease, Weight-Related Comorbidities and BMI >27 kg/m2.
Condition
Clinical Trials
Trial Phases
Physical Activity
24 Actively Recruiting
Not Applicable, Phase 1, Phase 2
Cardiovascular Diseases
0 Actively Recruiting
Type 2 Diabetes
164 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1
Cardiovascular Events
4 Actively Recruiting
Not Applicable
at least one weight-related comorbid condition
0 Actively Recruiting
Chronic Weight Management therapy
0 Actively Recruiting
Caloric Restriction
0 Actively Recruiting
Obesity
0 Actively Recruiting
Diet
5 Actively Recruiting
Not Applicable, Phase 1

Ozempic Reviews: What are patients saying about Ozempic?

5Patient Review
10/16/2022
Ozempic for Weight Loss Management for Overweight Person with BMI 27 to 29 and Weight-Related Comorbidity
I've been on this medication for four months now. I definitely noticed a change in my cravings; I used to love greasy foods, but now they don't appeal to me at all. I'm down 31 pounds since starting the medication, and I don't feel the need to snack constantly like I used to.
5Patient Review
10/29/2022
Ozempic for Weight Loss Management for an Obese Person
I've lost 35lbs since starting this treatment in July. The side effects were unpleasant at first, but they've gone away now and I'm really happy with the results. It's important to drink lots of water when you're on this medication, and to be patient as your body adjusts to it. The constipation was the hardest part for me, but it eventually went away.
5Patient Review
11/4/2022
Ozempic for Type 2 Diabetes Mellitus
This is the best medication I've ever been on. In just four months, it's helped me lower my A1C from 11 to 7. Plus, I haven't experienced any negative side effects.
4.3Patient Review
10/21/2022
Ozempic for Type 2 Diabetes Mellitus
Just feeling sick... otherwise this treatment is working well.
3Patient Review
11/8/2022
Ozempic for Weight Loss Management for an Obese Person
I get very nauseous from this medication, to the point of vomiting. The taste is incredibly unpleasant as well.
2.3Patient Review
11/5/2022
Ozempic for Type 2 Diabetes Mellitus
I took a one shot Monday night and was in the ER 5 days later. Spent over night and went home next night and was diagnosed with Pancreatitis. I have since been Diagnosed with Pancreas Cancer and seeing a Specialist Tuesday to see the depth of my Cancer. Ozempic may have alerted me of something far worst to come or it caused my Pancretitis. I won't be taking it again. Male 59
2Patient Review
11/7/2022
Ozempic for Weight Loss Management for an Obese Person
I would not recommend this drug for weight loss. It gave me terrible constipation that I have never experienced before in my life. I was on it for 5 weeks and stopped immediately after feeling these effects.
1.7Patient Review
10/30/2022
Ozempic for Type 2 Diabetes Mellitus
I have been experiencing gut pain, nausea, and headaches since I started taking this medication six weeks ago. I am also constantly constipated and have gained twelve pounds. While my A1C has dropped from 12.1 to 6.1 in the same time frame, I can't say that this drug is worth the other side effects I've experienced.
1.3Patient Review
10/16/2022
Ozempic for Weight Loss Management for Overweight Person with BMI 27 to 29 and Weight-Related Comorbidity
Allergic dermatitis is a terrible reaction to have. I had red splotches, dry patches, and hive-like itching all over my face. If anyone has experienced this, please let me know what the remedy was.
1Patient Review
10/7/2022
Ozempic for Type 2 Diabetes Mellitus
I was really surprised that this drug is allowed on the market after experiencing its terrible side effects firsthand. I had stomach aches, diarrhea and vomiting when I took the full dose. No wonder people lose weight when they're too sick to eat!
1Patient Review
10/18/2022
Ozempic for Type 2 Diabetes Mellitus
I have been struggling with chronic gastritis for a while now. I was put on Ozempic .25 five weeks ago, and my doctor has finally listened to me about the severe stomach pain I've been experiencing. This medication is being taken off of my regimen because it's made me feel incredibly ill--I have never felt this way from a medication before. It did help lower my blood sugar into the normal range, but the stomach pain is so unbearable that I would rather not have any relief than go through this again. If only I had found these reviews before starting this med...
1Patient Review
11/2/2022
Ozempic for Type 2 Diabetes Mellitus
After my first injection of this medication, I was beset by vomiting and diarrhea for six days straight. This led to extreme dehydration and a potassium deficiency that could've resulted in a heart attack. Needless to say, I won't be taking this drug any longer.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about ozempic

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What exactly does Ozempic do?

"Ozempic, when used with diet and exercise, has been shown to improve blood sugar in adults with type 2 diabetes. In adults with type 2 diabetes and known heart disease, Ozempic reduces the risk of major cardiovascular events such as stroke, heart attack, or death."

Answered by AI

Is Ozempic for weight loss?

"Ozempic is a medication for adults with type 2 diabetes. It is not a weight-loss drug. Ozempic, combined with diet and exercise, may improve blood sugar."

Answered by AI

What are the most common side effects of Ozempic?

"These are some of the side effects that may occur when using semaglutide. If you experience any of these effects, tell your doctor or pharmacist."

Answered by AI

What are the dangers of Ozempic?

"The pancreas can become inflamed, which is called pancreatitis. This can cause changes in vision, low blood sugar (hypoglycemia), kidney problems (kidney failure), serious allergic reactions, and gallbladder problems."

Answered by AI

Clinical Trials for Ozempic

Image of University of California, Los Angeles in Los Angeles, United States.

Tailored DPP for Prediabetes

17 - 25
All Sexes
Los Angeles, CA
The goal of this study is to enhance reach and uptake of diabetes prevention among young adults, with a focus on recruiting underserved and high-need students who face additional challenges, including food and financial insecurity. The specific aims are: Aim 1 - Evaluate the efficacy of an AYA-tailored version of the UC DPP for mitigating type 2 diabetes risk (i.e., weight change) in a pre/post pilot trial. The investigators hypothesize that the AYA-tailored intervention will be effective at producing 5% weight loss from baseline to program completion (at 9-months). Aim 2 - Assess the feasibility and acceptability of an AYA-tailored version of the UC DPP program. The investigators hypothesize that it will be feasible to recruit the desired number of participants given proposed innovative outreach strategies, and that the AYA-tailored intervention will be deemed acceptable to participants both qualitatively and in regards to their retention in the program at rates similar to the larger UC DPP. The investigators will recruit 80 UCLA undergraduate students. Participants will be asked to complete a brief screening online form to assess eligibility and to collect contact information. The PI and/or Research Assistants (RAs) will reach out to eligible participants to obtain informed consent and enroll them in the pilot trial. The investigators will randomize participants to the tailored DPP cohort vs control cohort. Control participants will be offered the opportunity to participate in the tailored DPP in the following academic year. The tailored DPP intervention will be online and asynchronously. Participants will be asked to complete the intervention lessons on their own time. Each lesson typically takes on average 15 minutes to complete. Control group will receive each intervention materials via e-mail for participants to review on their own time and will receive acceptability surveys. The interventions for the control group will be remote. A research assistant will meet with control participants via Zoom to explain the intervention materials. Control group will receive access to a study habits intervention, alcohol use intervention, and financial literacy intervention. At the end of each quarter (Fall, Winter, and Spring), both control and intervention participants will receive an email with a unique link to a brief REDCap survey to ascertain acceptability of sessions/lessons. Furthermore, participants will complete baseline and 9-month follow-up assessments. Participants will complete a 30 minute questionnaire and height/weight measurements will be collected by a RA. Participants will be asked to self-report weight and physical activity at the end of the fall and winter quarter; data will be collected via brief REDCap survey.
Recruiting
Has No Placebo
University of California, Los AngelesLauren E Wisk, PhD
Image of Medpace Clinical Pharmaology Unit in Cincinnati, United States.

PATAS for Type 2 Diabetes

18 - 55
All Sexes
Cincinnati, OH
The primary objective of Part 1 of this study is to evaluate safety and tolerability of single subcutaneous (SC) doses of PATAS in healthy subjects. The secondary objective of Part 1 of this study is to determine the pharmacokinetics (PK) of single SC doses of PATAS in healthy subjects. The primary objectives of Part 2 of this study are to evaluate the safety and tolerability of 4 weekly SC doses of PATAS in subjects with T2D; and to determine the PK and pharmacodynamics (PD) of 4 weekly SC doses of PATAS in subjects with T2D. The secondary objectives of Part 2 of this study are to evaluate the potential effect of multiple SC doses of PATAS on markers of glycemic control, as measured by glucose levels, insulin levels, and other metabolomic biomarkers; and to characterize the adverse event (AE) profiles of the various dose levels of PATAS.
Phase 1
Waitlist Available
Medpace Clinical Pharmaology UnitVincent Marion, Ph.D.AdipoPharma LLC
Have you considered Ozempic clinical trials? We made a collection of clinical trials featuring Ozempic, we think they might fit your search criteria.Go to Trials
Image of University of British Columbia - Okanagan in Kelowna, Canada.

Estrogen and Testosterone for Gender Differences in Physiology

18 - 40
All Sexes
Kelowna, Canada
Due to historical exclusion of females from research, there are gaps in the understanding of female physiology, how it differs from males, and how sex-specific hormones contribute. As a result, many diagnoses and treatments are based on male physiology and may not be appropriate or effective for females. Females consistently experience greater risk and report worse neurological outcomes in many diseases, including stroke, cardiac arrest, and dementia. As research in females progresses, differences between sexes and changes throughout the lifespan (e.g., puberty, menopause) highlight the importance of understanding the effects of sex and sex-specific hormones on the body. The brain is arguably the most important organ in the body, consuming 20% of the body's total energy. Previous research supports higher blood flow to the brain in females, and research in animals suggests hormones such as estrogen, progesterone, and testosterone are responsible. However, it is extremely difficult to isolate these hormones in humans, due to natural fluctuations (i.e., menstrual cycle). Therefore, the investigators plan to explore the direct role of these sex-specific hormones in regulating blood flow to the brain by blocking hormone production in healthy males and females and giving back testosterone and estrogen, respectively. The investigators will then conduct a range of tests to look at blood flow to the brain at rest and during various stressors. This research will provide crucial insight into how males and females differ in regulation of brain blood flow and inform new treatments and therapies to a wide range of brain injuries and diseases, improving outcomes and reducing the sex disparity in clinical pathways.
Waitlist Available
Has No Placebo
University of British Columbia - OkanaganPhilip Ainslie, PhD
Have you considered Ozempic clinical trials? We made a collection of clinical trials featuring Ozempic, we think they might fit your search criteria.Go to Trials
Image of Exercise Metabolism and Inflammation Laboratory in Okanagan, Canada.

Aerobic Exercise with Blood Flow Restriction for Type 2 Diabetes

19 - 64
All Sexes
Okanagan, Canada
The goal of this trial is to learn if blood flow restriction training with treadmill walking is possible for individuals living with type 2 diabetes. It will also learn about how the blood flow restriction with treadmill walking could improve health. The main questions it aims to answer are: Is 6 weeks of treadmill walking with blood flow restriction reasonable for people with type 2 diabetes to perform? Does treadmill walking with blood flow restriction training help manage type 2 diabetes better than just treadmill walking? Researchers will compare treadmill walking with blood flow restriction to treadmill walking without blood flow restriction to see if blood flow restriction works to manage type 2 diabetes based on fitness and blood sugar levels. Participants will: Perform treadmill walking with or without blood flow restriction for 96 minutes a week for 6 weeks. Visit the lab before and after the exercise for tests and questionnaires.
Waitlist Available
Has No Placebo
Exercise Metabolism and Inflammation Laboratory (+2 Sites)Martin Senechal, PhD
Image of Jefferson Health New Jersey in Sewell, United States.

Continuous vs Finger-stick Glucose Monitoring for Type 2 Diabetes in Pregnancy

18+
Female
Sewell, NJ
The purpose of this study is to compare patient adherence to blood sugar monitoring during pregnancy using two different measurement methods in pregnancies complicated by pregestational type 2 diabetes (T2DM). Pregnant patients with T2DM are at risk of having larger babies, babies with low sugar levels in the first 24 hours of life, higher rates of cesarean delivery, stillbirth (death of baby inside the womb), and hypertensive or high blood pressure disorders of pregnancy, such as preeclampsia. Prior studies have shown that treating high blood sugars in pregnancy with medications can reduce these risks. To determine the amount of medication needed, recording of blood sugar levels is necessary. This trial aims to determine whether continuous blood sugar monitors have improved patient recording of blood sugar levels over finger stick blood sugar measurements. Patients involved in the study will be assigned to either: 1. Fingerstick glucose monitoring (FSG) 2. Continuous glucose monitoring (CGM) Patients will be randomize in a 1:1 ratio. FSG Group: blood sugar is tested four times daily - once fasting and two hours after every meal (post-prandial). Blood will be tested using a glucometer, and values will be recorded in a blood sugar log from the time of enrollment to the time of delivery. CGM Group: A CGM sensor will be placed on the patient's arm for blood sugar collection every 3-5 minutes. This data is sent to a phone application from the time of enrollment to the time of delivery. These sensors will need to be replaced every 14 days. Percent adherence will be recorded from the time you were randomized to a study group until delivery.
Recruiting
Has No Placebo
Jefferson Health New Jersey (+1 Sites)
Image of McMaster University in Hamilton, Canada.

Health Coaching for Type 2 Diabetes and Mental Health

18+
All Sexes
Hamilton, Canada
Managing both type 2 diabetes and mental health challenges can be difficult, and many people do not receive care that supports both. This study looks at how virtual health coaching and support from interdisciplinary care teams can help people better manage their health. The purpose of this study is to test the effectiveness of a virtual health coaching program for adults living with type 2 diabetes and mental health challenges compared to usual care. The Technology-Enabled Collaborative Care for type 2 Diabetes and Mental health (TECC-DM) program includes weekly coaching calls, support from an interdisciplinary care team, and online tools to aid self-management. The findings from this study will be used to help improve services for people who have type 2 diabetes and co-occurring mental health symptoms.
Waitlist Available
Has No Placebo
McMaster UniversityCarly Whitmore, RN PhD
Have you considered Ozempic clinical trials? We made a collection of clinical trials featuring Ozempic, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security